Home » USA Broker Ratings » PRA Health Sciences – Consenus Indicates Potential 72.7% Upside

PRA Health Sciences – Consenus Indicates Potential 72.7% Upside

PRA Health Sciences with ticker code (PRAH) now have 13 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The range between the high target price and low target price is between 135 and 89 with the average target price sitting at 116.69. With the stocks previous close at 67.57 this now indicates there is a potential upside of 72.7%. The 50 day MA is 96.84 and the 200 day MA is 101.8. The company has a market capitalisation of $3,941m. Find out more information at: http://prahs.com

PRA Health Sciences, a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services. It also provides strategic solutions, such as embedded, functional services provider, staff augmentation, and custom-built development solutions, as well as commercialization services; and early development services for Phase I and Phase IIa studies, as well as bioanalytical analysis. The Data Solutions segment offers data, analytics, technology, and consulting solutions to the life sciences market. Its services include market intelligence services, such as targeting and compensation, and pharmaceutical audit suite services; consulting and services comprising brand analytics, managed markets, commercial effectiveness, and scientific studies/clinical hubs; and technology-enabled products and services that clients to access and analyze Symphony Health and integrated third-party data. PRA Health Sciences conducts clinical trials in the areas of pharmaceutical development, including oncology, immunology, central nervous system, inflammation, respiratory, cardiometabolic, and infectious diseases. The company was formerly known as PRA Global Holdings and changed its name to PRA Health Sciences in July 2014. PRA Health Sciences was founded in 1976 and is headquartered in Raleigh, North Carolina.

Join us on our new LinkedIn page

Follow us on LinkedIn